# Plain Language Summary of H.R. 2297

This bill puts a cap on how much money the FDA can spend from a special fund created by the Cures Act in 2024. Specifically, it limits spending from the "FDA Innovation Account" to no more than $50 million for that fiscal year. The FDA Innovation Account is a dedicated funding source designed to help the agency move faster on approving new drugs and medical devices, particularly for serious diseases.

To understand what this means in practical terms: the FDA uses this innovation money to speed up its review process for new treatments and to support research into breakthrough therapies. By capping it at $50 million, the bill is essentially restricting how much the agency can spend on these acceleration efforts. If the FDA would normally have access to more money from this account, this bill forces them to use less. This could potentially slow down the approval process for new medications and medical devices, since the agency would have fewer resources dedicated to expedited reviews.

The real-world impact would likely be felt by patients waiting for new treatments and by pharmaceutical companies developing new drugs. With a tighter budget, the FDA might take longer to review applications for new medicines, which means patients could face longer waits for access to potentially life-saving treatments. Drug companies might also experience delays in getting their products to market. The bill was introduced by a group of House members in March 2023 and was referred to the Committee on Energy and Commerce for consideration.

To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024.

Biggs, Andy

 <p>This bill limits FY2024 funding for the Food and Drug Administration (FDA) Innovation Account, which the FDA uses to implement provisions of the 21st Century Cures Act relating to the development of medical products.</p>